AbbVie Inc. (0QCV.IL)
| Previous close | 168.30 |
| Open | 168.00 |
| Bid | 160.08 x N/A |
| Ask | 175.78 x N/A |
| Day's range | 168.00 - 168.00 |
| 52-week range | 92.98 - 182.72 |
| Volume | |
| Avg. volume | 140,682 |
| Market cap | 302.225B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 34.57 |
| EPS (TTM) | 4.86 |
| Earnings date | 26 Apr 2024 |
| Forward dividend & yield | 5.92 (4.05%) |
| Ex-dividend date | 12 Oct 2023 |
| 1y target est | N/A |
PR NewswireAllergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesthetic treatment—can apply for a chance to be included in future brand campaigns. The first Allergan Aesthetics open casting call for BO
ZacksAbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
Investor's Business DailyThe Bad News Heading Into AbbVie's First-Quarter Earnings Report
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
